Targeted therapy in head and neck cancer

Tumori

Volumn 97, Issue 2, 2011, Pages 137-141

  Bianchini, Chiara ^a   Ciorba, Andrea ^a   Pelucchi, Stefano ^a   Piva, Roberta ^b   Pastore, Antonio ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cancer stem cells; Cancer treatment; Head and neck cancer; Targeting therapy

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CATENIN; CETUMIBAX; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR RECEPTOR; SURVIVIN; TELOMERASE; UNCLASSIFIED DRUG; WNT PROTEIN;

CANCER ADJUVANT THERAPY; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

EID: 79957651883     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700201     Document Type: Review

References (47)

1. Forastiere A, Koch W, Trotti A, Sidransky D: Medical progress-head and neck cancer. N Engl J Med, 345: 1890-1900, 2001.
2. Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med, 11: 981-1011, 2007. (Pubitemid 350037046)
3. Bianchini C, Ciorba A, Pelucchi S, Piva R, Pastore A: Head and neck cancer: the possible role of stem cells. Eur Arch Otorhinolaryngol, 265: 17-20, 2008. (Pubitemid 350160371)
4. Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A, Pirozzi G: The stem cell hypothesis in head and neck cancer. J Cell Biochem, 103: 408-412, 2008.
5. Prince ME, Ailles LE: Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol, 26: 2871-2875, 2008.
6. Braakhuis BJ, Leemans CR, BrakenhoV RH: Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol, 15: 113-120, 2005. (Pubitemid 40126242)
7. Hirata Y: Progression of cancer. Med Hypotheses, 52: 51-113, 1999.
8. Gollin SM: Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck, 23: 238-253, 2001.
9. Dietz A, Boehm A, Mozet C,Wichmann G, Giannis A: Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol, 265 Suppl: S3-12, 2008.
10. Mimeault M, Batra SK: Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells, 24: 2319-2345, 2006. (Pubitemid 44679695)
11. Mimeault M, Hauke R, Batra SK: Recent advances on the molecular mechanisms involved in drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther, 82: 252-264, 2007.
12. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer, 5: 275-284, 2005. (Pubitemid 40488633)
13. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov, 5: 997-1014, 2006. (Pubitemid 44835127)
14. Rubin LL, de Sauvage FJ: Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov, 5: 1026-1033, 2006. (Pubitemid 44835129)
15. Roberg K, Jonsson AC, Grenman R, Norberg-Spaak L: Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors. Head Neck, 29: 325-334, 2007. (Pubitemid 46623497)
16. Mimeault M, Batra S: Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol, 18: 1605-1619, 2007. (Pubitemid 47506246)
17. Mimeault M, Batra SK: Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev, 26: 203-214, 2007. (Pubitemid 46452192)
18. Fodde R, Brabletz T:Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol, 19: 150-158, 2007. (Pubitemid 46386404)
19. Zhang Q, Chen G, Liu X, Qian Q:Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res, 17: 89-99, 2007. (Pubitemid 46279233)
20. Goerner M, Seiwert TY, Sudhoff H: Molecular targeted therapies in head and neck cancer - An update of recent developements. Head Neck Oncol, 2: 8-10, 2010.
21. Razak AR, Siu LL, Le Tourneau C: Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol, 22: 212-220, 2010.
22. Le Tourneau C, Siu LL: Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Current Opinion in Oncology, 20: 256-263, 2008. (Pubitemid 351507544)
23. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 25: 2171-2177, 2007. (Pubitemid 46954639)
24. Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer, 94: 631-636, 2006. (Pubitemid 43361892)
25. Stewart JSW, Cohen EEW, Licitra L: A phase III randomized parallel group study of gefitinib (RESSA) versusmethotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck [abstract]. In: American Association for Cancer Research Annual Meeting: Proceedings; 14-18 Apr 2007; Los Angeles, Philadelphia: AACR; 2007, Abstract 3522.
26. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol, 23: 5568-5577, 2005.
27. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol, 23: 5578-5587, 2005.
28. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab inmetastatic / recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol, 23: 8646-8654, 2005. (Pubitemid 46211507)
29. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E: Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol, 25: 2178-2183, 2007. (Pubitemid 46954640)
30. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A,Vokes EE: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol, 10: 247-257, 2009.
31. Matta A, Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol, 1: 6-10, 2009.
32. Slaughter DP, Southwick HW, Smejkal W: "Field cancerization" in oral stratified squamous epithelium. Cancer, 6: 963-968, 1953.
33. Leemans CR, Tiwari R, Nauta JJ, van derWaal I, Snow GB: Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer, 73: 187-190, 1994.
34. Braakhuis BJ, Brakenhoff RH, Leemans CR: Gene expression profiling in head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg, 18: 67-71, 2010.
35. Ha PK, Califano JA: The Molecular Biology of Mucosal Field Cancerization of the Head and Neck. Critical Reviews in Oral Biology & Medicine, 14: 363-369, 2003. (Pubitemid 44560790)
36. Mahfouz ME, Rodrigo JP, Takes RP, Elsheikh MN, Rinaldo A, Brakenhoff RH, Ferlito A: Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol, 267: 851-860, 2010.
37. Langer CJ: Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer, 112: 2635-2645, 2008.
38. Mimeault M, Batra SK: Recent insights into the molecular mechanisms involved in aging and themalignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev, 8: 94-112, 2009.
39. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5: 219-234, 2006. (Pubitemid 43336035)
40. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A: Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck, 30: 667-674, 2008. (Pubitemid 351656109)
41. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res, 13: 4291-4299, 2007. (Pubitemid 47105993)
42. Hong DY, Lee BJ, Lee JC, Choi JS,Wang SG, Ro JH: Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma. Clin Exp Otorhinolaryngol, 2: 186-192, 2009.
43. Wang X, Hao MW, Dong K, Lin F, Ren JH, Zhang HZ: Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res, 32: 1263-1269, 2009.
44. Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S, Fujiwara T: Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res, 15: 2335-2343, 2009.
45. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA,Wagener MM, Drenning SD, Tweardy DJ: Levels of TGF alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst, 90: 824-832, 1998. (Pubitemid 28280548)
46. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ: Down modulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69: 55-62, 1998. (Pubitemid 28099922)
47. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO: Cyclooxygenase-2: a novelmolecular target for the prevention, treatment of head, neck cancer. Head Neck, 24: 792-799, 2002. (Pubitemid 34857307)